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HEPATIC allografts are unusually resistant to hyper-
acute rejection. and they function well despite the 
presence of antidonor Iymphocytotoxic antibody (positive 
crossmatch) with very few exceptions. 1-6 We have previ-
ously reported that 1- and ~-year hepatic graft survivals 
were not adversely affected by the lymphocytotoxic anti-
body and that a positive crossmatch should not be consid-
ered as a contraindicatioo for hepatic allotrans-
plantation.·" It is true. howe .... er. that crossmatch-positive 
hepatic grafts have been lost repeatedly for inadequately 
explained reasons at our center as well as at other 
centers.7• IO 
The improvement in organ preservation. provided by 
the University of Wisconsin (UW) solution. might have 
nearly eliminated the intrinsic graft-related causes of loss 
from the analysis. ll . ll 
At our center the incide~ of so-called primary non-
function of liver graft used to be between 3.5% and 7.4% 
with Euro-Collins solution,'·11 but it has been less than 
2.0% with UW solution for the last 3 years. II The inci-
dence of early hepatic retransplantation has also decreased 
from 20% to 11.3%." Thus. we decided to examine. for 
the third time, the effect of antidonor lymphocytotoxic 
antibody upon graft survival. 
CASE MATERIALS AND METHODS 
Cyclosporine (CyA) Group 
During the 2-year period betwec October 1987 and September 
1989.631 adult patients (18 yean old or older) received their fi~t 
orthotopic liver transplantation under CyA·steroid therapy at the 
U nive~ity Health Center of Pittsburgh. Three of the 63 J patients 
received ABO blood group incompatible grafts and 28 othe~ were 
not tested for Iymphocytotoxic antibody against a specific donor. 
These 31 patients were excluded from this study. Thus. the 
patients of the CyA group consisted of a total of 600 fi~tKgrrt 
recipients. 
FK 506 Group 
During the 9-month period betWeeD August 1989 and April 1990. 
166 adult patients received primary hepatic allogrUts under FK 
506 and low-(!ose steroid thenlPY. Eleven patients were excluded 
from the study because the cr05smaich test was not performed. 
There was no ABO blood croup iDcompatible transplant in this 
group. Thus. the FK S06 poup comisted of 155 adult patients () 8 
years old or older). 
Crossmatc:h Test 
The recipients sera obtained immediately before liver transplan-
tation were tested for cytotoxic IIIbbody against donor fymp~ 
cytes (unfnlctionated) at room tempenlture or 37"C by trypan blue 
dye exclusion. with a »-minute incubation with serum and 
6O-minute incubation with complement. The crossmatch test was 
interpreted as positive (+) \I.-ben more than 30% of lymphocytes 
were killed. and it was considered negative (-) when less than 
109C of cells were killed. When 10% to 30% of donor lymphocytes 
were killed by recipient serum. the crossmatch was interpreted as 
weakly positive (:). 
Organ Preservation 
All of the liver allografts in this study were preserved with the UW 
solution,l3 and not with Euro-Collins solution which was used in 
our previous reports. 4..\ 
Graft Survival. Follow·Up. and Statistics 
Hepatic allograft was considered "lost" when the recipient died 
with or without good gra(t function or when the graft was replaced 
by another because of poor or nonfunction. The survival nltes 
were calculated by the life table method of Kaplan·Meier. The 
results were summarized as 0( June 30. 1990. with a minimum 
follow·up of9 months in the CyA group and of2 months in the FK 
506 group. 
Statistical comparisons were made by the method of Breslow. 
by student I test and by chi-square test. The difference was 
considered statistically significant when P < .OS. 
RESULTS 
Incidence of Positive CrossmaICh 
Of the 600 patients in the Cy A group. the cross match was 
positive (greater than 3O'it killing) against the first hepatic 
allograft donors in 72 (I2.O?f) recipients. weakly positive 
(10% to 30% killing) in 75 (12.5%) recipients, and negative 
(less than 10% killing) in 453 (75.5%) recipients. 
In the FK 506 group. the crossmatch was positive 
against the first hepatic dooor in 2\ (13.5%) of the 155 
recipients. weakly positive in 12 (7.8%) recipients. and 
negative in 122 (78.7%) recipients. The incidence of posi-
tive crossmatch for the first hepatic allograft was similar 
between the CyA group and the FK 506 group. 
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Table 1. Ac:tuatIIII Graft Surv1v81 In the CyA Group 
I IAonIh 3 Mot-.8 6Monh lV_ 2 V .... 
-crossmatc:t1 
70.8::!: 5.4 66.7::!: 5.6 62.5 ::!: 5.7 59.7:!: 5.8 504.9:: 6.0 pgsiIJYe 
(n" 72) (n = 49) (n = 46) (n = 44) (n .. 22) (n = 15) 
Well/1.. positive 84.0::!: 4.2 81.3::!: 4.5 76.0::!: 4.9 73.2:!: 5.1 69.9:: 5.4 
(n'" 75) (n = 63) (n = 58) (n = 54) (n = 25) (n = 21) 
NegaIiYe 83.9:: 1.7 78.4::!: 1.9 74.2 ::!: 2.1 69.9 ::!: 2.2 66.8:: 2.3 
(n" 453) (n = 378) (n = 353) (n=311) (n = 139) (n = 83) 
Total 82.2::!: 1.6 n.3::!: 1.7 72.9:::!: 1.8 69.1 ::!: 1.9 65.7::!: 2.0 
(n ,,6(0) (n = 490) (n = 457) (n = 409) (n = 186) (n=119) 
-p < .05: 70.8 :!: 5.4 VI 84.0 = 4.2; 70.8 :!: 5.4 VI 83.9 = 1.7; 66.7 ::: 5.6 VI 78.4 : 1.9; 66.7 = 5.6 VI 81.3 ::: 4.5; 62.5 = 5.7 YS 74.2 = 2.1. 
Graft Survival 
The survival of first hepatic allografts under CyA-steroid 
therapy was compared among the crossmatch-positive 
grafts. the weakly positive (10% to 30% killing) grafts, and 
the negative grafts listed in Table I. There was no statis-
tically significant difference in the survival curves among 
the three groups of grafts (P = .07 by Breslow method). 
However, I-month and 3-month survival rates of the 
crossmatch positive grafts were significantly lower than 
those of the negative grafts and those of the weakly 
positive grafts (by Student's t test). At 6 months, the 
survival rate of the crossrnatch-positive graft was still 
significantly lower than that of the crossmatch-negative 
graft (Table I). 
One-, 3-, and 6-month survival rates of primary hepatic 
allografts under FK 506 and low-dose steroid therapy are 
shown in Table 2. The survivals of the crossmatch-positive 
grafts were lower than those of the negative grafts and 
those of the weakly positive grafts, but the differences 
were not statistically significant. 
Main Causes of Graft Loss 
Liver grafts were often lost to multiple causes and it was 
difficult to select a single main cause of graft loss. How-
ever. the main cause of graft loss was categorized to the 
Table 2. Actuarial Graft Survival In FK 508 Group 
1 MonII 3 MonIII 6..".. 
Crossmalch 
Positive 75.0::!: 10.0 69.4:!: 10.0 69.4::!: 10.0 
(n = 21) (n = 16) (n" 14) (n" 6) 
Weak pes- 91.7::!: 8.0 82.9:!: 11.0 622::!: 15.0 
iN 
(n .. 12) (n - 11) (n - 9) (n: 5) 
Negative 91.7:: 3.0 87.5::!: 3.0 86.4::!: 3.0 
(n" 122) (n - 111) (n • 96) (n = 51) 
Teal 89.5 :t 2.0 84.8:t 3.0 82.3 :t 3.0 
(n. 155) (n" 138) (n"119) en - 62) 
best of our knowledge in the Cy A group as shown in Table 
3. 
Rejection was the most common cause of primary liver 
allograft failure when the crossmatch was positive. Actu-
ally within 1 month aftertransplantation, 6 (8.3%) of the 72 
crossmatch-positive grafts were lost to rejection, but only 
1 (1.3%) of the 75 crossmatch weakly positive grafts and 
only 8 (1.8%) of the 453 crossmatch-negative grafts were 
lost to the same cause. During the entire observation 
period, 9 (12.5%) of the 72 crossmatch-positive grafts and 
20 (4.4%) of the 453 crossmatch-negative grafts were lost 
to rejection. The incidence of graft loss to rejcction was 
significantly higher in the crossmatch-positive group than 
in the negative group (P < .05). and it was most remark-
able during the first month as shown in Table 3 and Figure 
I. There was no difference in the incidence of graft loss to 
other various causes among the three groups (Table 3). 
DISCUSSION 
This study demonstrated for the first time that anti donor 
Iymphocytotoxic antibody (positive crossmatch) adversely 
affected the survi"als of primary hepatic allografts during 
the first 6 months after transplantation (Table I). The 
reason appears to be immunological, as the grafts were lost 
to rejection significantly more often in positive crossmatch 
than in negative crossmatch transplant (Table 2 and Figure 
I). 
Our previous reports··5 had failed to show any signifi-
cant effcct of positive crossmatch upon the hepatic graft 
survivals. The graft survivals were essentially equal be-
tween the crossmatch-positive group and the negative 
group. In our early report,· the primary graft survival rate 
was only 50% al I year, and the mortality related to 
operation or graft loss due to technical problems were 17% 
without the use of veno-venous bypass. In our last report, 5 
the primary graft survival rate increased to 63% at I year 
with the routine use of vena-venous bypass. In both 
reports, the liver grafts were preserved with Elll'tH:ollins 
solution. 
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Tible 3. Main Cause of Grin lou In the CyA Group 
()'1Mon11l 
Crossmalc:n ("4) CP WP 
Primary nonlundion 7 (9.7) 3 (4.0) 
Technical failure 5(6.9) 6(8.0) 
Rejection 6(8.3) 1 (1.3) 
InfectiOn 1 (1.4) 1 (1.3) 
Others 4 (5.6) 1 (1.3) 
Undetennined 0 0 
Total graft loss 23 (31.9) 12 (16.0) 
T ota! grafts 72 75 
AIlbrNaIionl: CPo CIllamItch pos/IIYe; WP. weak posiINe; N. negltiYe. 
P < .OS: 6 (8.3) \/I' (1.1); 9 (12.5) \II 20 (404). 
In the present study, the liver grafts were preserved with 
UW solution, the primary graft survival further increased 
to 70% at I year, and the operative mortaJity and graft loss 
due to technicaJ problems decreased to 8%. The rate of 
graft primary nonfunction has decreased to less than 2% 
with UW solution. and the rate of early retransplantation 
has been reduced to 11.3% in recent years. II 
Although the basic immunosuppressive therapy in these 
studies was the combination of Cy A and steroid, supple· 
mented by ALG, andior azathioprine. the rate of graft loss 
to rejection and to infectious death decreased from 13% 
and 9% to 5.4% and 4%. respectively. Only after these 
significant advances in surgicaJ techniques, organ preser-
vation, and perioperative patient care, including the treat-
men! of infection and rejection, were the adverse effects of 
positive crossmatch final.ly disclosed in the hepatic trans-
plantation. 
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FIg 1. The cumulative incidence of graft loss to rejection was 
compared between the crossmatch-positive grafts and the nega-
tive grafts. The inddence in !he former was significantly higher 
than In the Ianer for the first 9 months after liver transplantation 
(P < .05). 
1·3 MonIhs 
N CP WP N 
29 (6.4) 0 0 0 
22 (4.9) 1 (2.0) 0 4 (1.t) 
8 (1.8) 1 (2.0) 2 (3.2) 3 (0.8) 
4 (0.9) 1 (2.0) 0 9 (2.4) 
11 (2.4) 0 0 9 (2.4) 
1 (0.2) 0 0 0 
75 (16.6) 3 (6.1) 2 (3.2) 25(6.6) 
453 49 63' 378 
The method of antidonor Iymphocytotoxic antibody 
assay (crossmatch test) used in this study is primitive, but 
it has been a practical and dependable test in clinical 
transplantation over a long period of time. Even with this 
rather primitive crossmatch test. this study finally demon-
strated the significant deterious effects of cytotoxic anti-
body upon early hepatic allograft survivaJs. Since Novem-
ber 1989, we have adapted antidonor T-Iymphocytotoxic 
antibody assay with dithiothreitol (OIT) treatment of 
recipient sera at 3rc (T-warm crossmatch with OIT 
treatment).14-16 Although the results are still preliminary, 
the presence of high titer antibody with this new method of 
assay appears to predict severe early hepatic graft mal-
function. Timely treatment of this severe immunological 
insult with a bolus of steroid injection andior 0 KTI usuaJly 
avoids the early retransplantation of the liver. 
Antidonor Iymphocylotoxic antibody assay has become 
an important laboratory lest for immunosuppressive ther-
apy in the earliest posttransplant period. if not yet for the 
selection of the hepatic recipient. 
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